Immunological thresholds in neurological gene therapy: Highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells

Neuron Glia Biology

Volumn 2, Issue 4, 2006, Pages 309-321

  Barcia, Carlos ^a   Gerdes, Christian ^c   Xiong, Wei Dong ^a   Thomas, Clare E ^c   Liu, Chunyan ^a   Kroeger, Kurt M ^a   Castro, Maria G ^a,b   Lowenstein, Pedro R ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adenovirus; Gene therapy; Neuroimmunology; Promoter; Threshold

Indexed keywords

ADENOVIRUS HUMAN CYTOMEGALOVIRUS BETA GALACTOSIDASE; ADENOVIRUS HUMAN CYTOMEGALOVIRUS HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE; ADENOVIRUS VECTOR; ANTIGEN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFECTION; BRAIN NERVE CELL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE INCREASE; GENE EXPRESSION; GENE THERAPY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; MALE; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; RECOMBINANT GENE; SYNAPSE; T LYMPHOCYTE; TRANSGENE; VIRUS INFECTION;

ADENOVIRIDAE;

EID: 34447502243     PISSN: 1740925X     EISSN: 17410533     Source Type: Journal    
DOI: 10.1017/S1740925X07000579     Document Type: Article

References (71)

1. Akrigg A., Wilkinson G.W. and Oram J.D. (1985) The structure of the major immediate early gene of human cytomegalovirus strain AD169. Virus Research 2, 107-121.
2. Amalfitano A. and Parks R.J. (2002) Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Current Gene Therapy 2, 111-133.
3. Baltzis D., Qu, L.K. Papadopoulou S., Blais J.D., Bell J.C., Sonenberg N. et al. (2004) Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR. Journal of Virology 78, 12747-12761.
4. Barcia C., Thomas C.E., Curtin J.F., King G.D., Wawrowsky, K. Candolfi M. et al. (2006) In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. Journal of Experimental Medicine 203, 2095-2107.
5. Bemelmans A.P., Horellou P., Pradier L., Brunet I., Colin P. and Mallet J. (1999) Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Human Gene Therapy 10, 2987-2997.
6. Bett A.J. (1995). Construction and characterization of recombinant human adenovirus type 5 vectors. PhD Thesis, McMaster University, Hamilton, Ontario, Canada.
7. Biglari A., Bataille D., Naumann U., Weller M., Zirger J., Castro M.G. et al. (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Therapy 11, 721-732.
8. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.J., Mallet J. et al. (1997) Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proceedings of the National Academy of Sciences of the U.S.A. 94, 8818-8823.
9. Binder G.K. and Griffin D.E. (2003) Immune-mediated clearance of virus from the central nervous system. Microbes and Infection 5, 439-448.
10. Bjorklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C. and Mandel R.J. (2000) Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Research 886, 82-98.
11. Bonizzi G. and Karin M. (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends in Immunology 25, 280-288.
12. Braz J., Beaufour C., Coutaux A., Epstein A.L., Cesselin F., Hamon M. et al. (2001) Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. Journal of Neuroscience 21, 7881-7888.
13. Byrnes A.P., MacLaren R.E. and Charlton H.M. (1996a) Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. Journal of Neuroscience 16, 3045-3055.
14. Byrnes A.P., Rusby J.E., Wood M.J. and Charlton H.M. (1995) Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66, 1015-1024.
15. Byrnes A.P., Wood M.J. and Charlton H.M. (1996b) Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Therapy 3, 644-651.
16. Chiocca E.A., Abbed K.M., Tatter S., Louis D.N., Hochberg F.H., Barker F. et al. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapeutics 10, 958-966.
17. Cope D.K. and Lariviere W.R. (2006) Gene therapy and chronic pain. ScientificWorldJournal 6, 1066-1074.
18. Cowsill C., Southgate T.D., Morrissey G., Dewey R.A., Morelli A.E., Maleniak T.C. et al. (2000) Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK. Gene Therapy 7, 679-685.
19. Dewey R.A., Morrissey G., Cowsill C.M., Stone, D, Bolognani F., Dodd N.J. et al. (1999) Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nature Medicine 5, 1256-1263.
20. Dion L.D., Fang J. and Garver R.I. Jr (1996) Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. Journal of Virology Methods 56, 99-107.
21. Do Thi N.A., Saillour, P. Ferrero L., Dedieu J.F., Mallet J. and Paunio T. (2004) Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Therapy 11, 746-756.
22. Eck S.L., Alavi J.B., Judy K., Phillips P., Alavi A., Hackney D. et al. (2001) Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial.Human Gene Therapy 12, 97-113.
23. Ehtesham M., Black K.L. and Yu J.S. (2004) Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11, 192-207.
24. Finegold A.A., Mannes A.J. and Iadarola M.J. (1999) A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Human Gene Therapy 10, 1251-1257.
25. Geddes B.J., Harding T.C., Lightman S.L. and Uney J.B. (1997) Long-term gene therapy in the CNS: reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nature Medicine 3, 1402-1404.
26. Gerdes C.A., Castro M.G. and Lowenstein P.R. (2000) Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Molecular Therapeutics 2, 330-338.
27. Glover C.P., Bienemann A.S., Hopton M., Harding T.C., Kew J.N. and Uney J.B. (2003) Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used. Journal of Gene Medicine 5, 554-559.
28. Gondi C.S., Lakka S.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M. et al. (2004) Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Research 64, 4069-4077.
29. Griffin D.E. (2003) Immune responses to RNA-virus infections of the CNS. Nature Reviews Immunology 3, 493-502.
30. Hao S., Mata M., Wolfe D., Huang S., Glorioso J.C. and Fink D.J. (2003) HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Molecular Therapeutics 8, 367-375.
31. Hsu L.C., Park, J.M. Zhang K., Luo J.L., Maeda S., Kaufman R.J. et al. (2004) The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 428, 341-345.
32. Hurtado-Lorenzo A., Millan E., Gonzalez-Nicolini V., Suwelack D., Castro M.G. and Lowenstein P.R. (2004) Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration. Molecular Therapeutics 10, 507-524.
33. Ideguchi M., Kajiwara K., Yoshikawa K., Uchida T. and Ito H. (2000) Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain. Neuroscience 95, 217-226.
34. Immonen A., Vapalahti M., Tyynela K., Hurskainen H., Sandmair A., Vanninen R. et al. (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Molecular Therapeutics 10, 967-972.
35. Isler J.A., Skalet A.H. and Alwine J.C. (2005) Human cytomegalovirus infection activates and regulates the unfolded protein response. Journal of Virology 79, 6890-6899.
36. Kagi D., Ledermann B., Burki K., Zinkernagel R.M. and Hengartner H. (1996) Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annual Review of Immunology 14, 207-232.
37. Kajiwara K., Byrnes A.P., Charlton H.M., Wood M.J. and Wood K.J. (1997) Immune responses to adenoviral vectors during gene transfer in the brain. Human Gene Therapy 8, 253-265.
38. Khanna K.M., Lepisto A.J., Decman V. and Hendricks R.L. (2004) Immune control of herpes simplex virus during latency. Current Opinion in Immunology 16, 463-469.
39. Lowenstein P.R. (2002) Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends in Immunology 23, 23-30.
40. Lu C.Y., Chou A.K., Wu C.L., Yang C.H., Chen J.T., Wu P.C. et al. (2002) Gene-gun particle with pro-opiomelanocortin cDNA produces analgesia against formalin-induced pain in rats. Gene Therapy 9, 1008-1014.
41. Maleniak T.C., Darling J.L., Lowenstein P.R. and Castro M.G. (2001) Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Therapy 8, 589-598.
42. Milligan E.D., Langer S.J., Sloane E.M., He L., Wieseler-Frank J., O'Connor K. et al. (2005a) Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eurropean Journal of Neuroscience 21, 2136-2148.
43. Milligan E.D., Sloane E.M., Langer S.J., Cruz P.E., Chacur M., Spataro L. et al. (2005b) Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Molecular Pain 1, 9.
44. Mittoux V., Joseph J.M., Conde F., Palfi S., Dautry C., Poyot T. et al. (2000) Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Human Gene Therapy 11, 1177-1187.
45. Mittoux V., Ouary S., Monville C., Lisovoski F., Poyot T., Conde F. et al. (2002) Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. Journal of Neuroscience 22, 4478-4486.
46. Patterson C.E., Lawrence D.M., Echols L.A. and Rall G.F. (2002) Immune-mediated protection from measles virus-induced central nervous system disease is noncytolytic and gamma interferon dependent. Journal of Virology 76, 4497-4506.
47. Paxinos G. (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press.
48. Pradat P.F., Kennel P., Naimi-Sadaoui S., Finiels F., Orsini C., Revah F. et al. (2001) Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. Human Gene Therapy 12, 2237-2249.
49. Rall G.F., Mucke L. and Oldstone M.B. (1995) Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo. Journal of Experimental Medicine 182, 1201-1212.
50. Ralph G.S., Bienemann A., Harding T.C., Hopton M., Henley J. and Uney J.B. (2000) Targeting of tetracycline-regulatable transgene expression specifically to neuronal and glial cell populations using adenoviral vectors. Neuroreport 11, 2051-2055.
51. Sandmair A.M., Loimas S., Puranen P., Immonen A., Kossila M., Puranen M. et al. (2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Human Gene Therapy 11, 2197-2205.
52. Scheuner D., Gromeier M., Davies M.V., Dorner A.J., Song B., Patel R.V. et al. (2003) The double-stranded RNA-activated protein kinase mediates viral-induced encephalitis. Virology 317, 263-274.
53. Shand N., Weber F., Mariani L., Bernstein M., Gianella-Borradori A., Long Z. et al. (1999) A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Human Gene Therapy 10, 2325-2335.
54. Shering A.F., Bain D., Stewart K., Epstein A.L., Castro M.G., Wilkinson G.W. and Lowenstein P.R. (1997) Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. Journal of General Virology 78, 445-459.
55. Smith-Arica J.R., Morelli A.E., Larregina A.T., Smith J., Lowenstein P.R. and Castro M.G. (2000) Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression. Molecular Therapeutics 2, 579-587.
56. Southgate T., Bain D., Fairbanks L.D., Morelli, A. Larregina A., Simmonds H.A. et al. (2000a) Adenoviruses encoding HPRT correct the biochemical abnormalities fully only in HPRT-deficient human cell lines: importance of species differences. Advances in Experimental and Medical Biology 486, 35-40.
57. Southgate T., Kingston P. and Castro M.G. (2000b) Gene transer into neural cells in vivo using adenoviral vectors. In Gerfen C.R., McKay R., Rogawski M.A., Sibley D.R. and Skolnick P. (eds) Current Protocols in Neuroscience. John Wiley and Sons, pp 4.23.1-4.23.40, 4.23.21-24.23.40.
58. Sterio D.C. (1984) The unbiased estimation of number and sizes of arbitrary particles using the disector. Journal of Microscopy 134, 127-136.
59. Suwelack D., Hurtado-Lorenzo A., Millan E., Gonzalez-Nicolini V., Wawrowsky K., Lowenstein P.R. et al. (2004) Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease. Gene Therapy 11, 1742-1752.
60. Tada T., Nguyen J.B., Hitoshi Y., Watson N.P., Dunn J.F., Ohara S. et al. (2005) Diffuse encephaloventriculitis and substantial leukoencephalopathy after intraventricular administration of recombinant adenovirus. Neurological Research 27, 378-386.
61. Thomas C.E., Abordo-Adesida E., Maleniak T.C., Stone D., Gerdes G. and Lowenstein P.R. (2000a) Gene transfer into rat brain using adenoviral vectors. In Gerfen C.R., McKay R., Rogawski M.A., Sibley D.R. and Skolnick P. (eds) Current Protocols in Neuroscience. John Wiley and Sons, pp 4.23.1-4.23.40, 4.23.21-24.23.40.
62. Thomas C.E., Birkett D., Anozie I., Castro M.G. and Lowenstein P.R. (2001a) Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Molecular Therapeutics 3, 36-46.
63. Thomas C.E., Birkett D., Anozie I., Castro M.G. and Lowenstein P.R. (2001b) Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Molecular Therapeutics 3, 36-46.
64. Thomas C.E., Schiedner G., Kochanek S., Castro M.G. and Lowenstein P.R. (2000b) Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proceedings of the National Academy of Sciences of the U.S.A. 97, 7482-7487.
65. Thomas C.E., Schiedner G., Kochanek S., Castro M.G. and Lowenstein P.R. (2001c) Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Human Gene Therapy 12, 839-846.
66. Trask T.W., Trask R.P., Aguilar-Cordova E., Shine H.D., Wyde P.R., Goodman J.C. et al. (2000) Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Molecular Therapeutics 1, 195-203.
67. Wilkinson G.W. and Akrigg A. (1992) Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Research 20, 2233-2239.
68. Wood M.J., Charlton H.M., Wood K.J., Kajiwara K. and Byrnes A.P. (1996) Immune responses to adenovirus vectors in the nervous system. Trends in Neurosciences 19, 497-501.
69. Yao M.Z., Gu J.F., Wang J.H., Sun L.Y., Liu H. and Liu X.Y. (2003) Adenovirus-mediated interleukin-2 gene therapy of nociception. Gene Therapy 10, 1392-1399.
70. Zermansky A.J., Bolognani F., Stone D., Cowsill C.M., Morrissey G., Castro M.G. et al. (2001) Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS. Molecular Therapeutics 4, 490-498.
71. Zou L., Zhou H., Pastore L. and Yang K. (2000) Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Molecular Therapeutics 2, 105-113.